Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus

30 Nov 2021

Abstract excerpt

Vesicular stomatitis virus (VSV) is a promising oncolytic virus (OV) against different malignancies, including pancreatic ductal adenocarcinoma (PDAC). Our previous studies have demonstrated that VSV-based OVs are effective against the majority of tested human PDAC cell lines. However, some PDAC cell lines are resistant to VSV. PDAC is one of the deadliest types of human malignancies in part due to intrinsic or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to Virology and Viral Diseases
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34977342
DOI: 10.1016/j.omto.2021.11.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virusPMID 34977342Read ↗

Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and SolutionsSemantic proximity Read ↗

Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.Semantic proximity Read ↗

Vesicular Stomatitis Virus as an Oncolytic Agent against Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.Semantic proximity Read ↗

Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cellsSemantic proximity Read ↗

Oncolytic virotherapy for pancreatic cancer.Semantic proximity Read ↗

Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer.Semantic proximity Read ↗

Oncolytic Vesicular Stomatitis Virus: Optimisation Strategies for Anti-Cancer TherapiesSemantic proximity Read ↗

Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis VirusSemantic proximity Read ↗

Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancerSemantic proximity Read ↗

OvirusTdb: A database of oncolytic viruses for the advancement of therapeutics in cancerSemantic proximity Read ↗

The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.